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Abstract: In pregnancy, iron deficiency and iron overload increase the risk for adverse pregnancy out-
comes, but the effects of maternal iron status on long-term child health are poorly understood. The aim
of the study was to systematically review and analyze the literature on maternal iron status in preg-
nancy and long-term outcomes in the offspring after birth. We report a systematic review on maternal
iron status during pregnancy in relation to child health outcomes after birth, from database inception
until 21 January 2021, with methodological quality rating (Newcastle-Ottawa tool) and random-effect
meta-analysis. (PROSPERO, CRD42020162202). The search identified 8139 studies, of which 44 were
included, describing 12,7849 mother-child pairs. Heterogeneity amongst the studies was strong. Method-
ological quality was predominantly moderate to high. Iron status was measured usually late in pregnancy.
The majority of studies compared categories based on maternal ferritin, however, definitions of iron de-
ficiency differed across studies. The follow-up period was predominantly limited to infancy. Fifteen
studies reported outcomes on child iron status or hemoglobin, 20 on neurodevelopmental outcomes, and
the remainder on a variety of other outcomes. In half of the studies, low maternal iron status or iron
deficiency was associated with adverse outcomes in children. Meta-analyses showed an association of
maternal ferritin with child soluble transferrin receptor concentrations, though child ferritin, transferrin
saturation, or hemoglobin values showed no consistent association. Studies on maternal iron status above
normal, or iron excess, suggest deleterious effects on infant growth, cognition, and childhood Type 1
diabetes. Maternal iron status in pregnancy was not consistently associated with child iron status after
birth. The very heterogeneous set of studies suggests detrimental effects of iron deficiency, and possibly
also of overload, on other outcomes including child neurodevelopment. Studies are needed to determine
clinically meaningful definitions of iron deficiency and overload in pregnancy.
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Abstract: In pregnancy, iron deficiency and iron overload increase the risk for adverse pregnancy
outcomes, but the effects of maternal iron status on long-term child health are poorly understood.
The aim of the study was to systematically review and analyze the literature on maternal iron status
in pregnancy and long-term outcomes in the offspring after birth. We report a systematic review on
maternal iron status during pregnancy in relation to child health outcomes after birth, from database
inception until 21 January 2021, with methodological quality rating (Newcastle-Ottawa tool) and
random-effect meta-analysis. (PROSPERO, CRD42020162202). The search identified 8139 studies,
of which 44 were included, describing 12,7849 mother–child pairs. Heterogeneity amongst the
studies was strong. Methodological quality was predominantly moderate to high. Iron status
was measured usually late in pregnancy. The majority of studies compared categories based on
maternal ferritin, however, definitions of iron deficiency differed across studies. The follow-up period
was predominantly limited to infancy. Fifteen studies reported outcomes on child iron status or
hemoglobin, 20 on neurodevelopmental outcomes, and the remainder on a variety of other outcomes.
In half of the studies, low maternal iron status or iron deficiency was associated with adverse
outcomes in children. Meta-analyses showed an association of maternal ferritin with child soluble
transferrin receptor concentrations, though child ferritin, transferrin saturation, or hemoglobin values
showed no consistent association. Studies on maternal iron status above normal, or iron excess,
suggest deleterious effects on infant growth, cognition, and childhood Type 1 diabetes. Maternal
iron status in pregnancy was not consistently associated with child iron status after birth. The very
heterogeneous set of studies suggests detrimental effects of iron deficiency, and possibly also of
overload, on other outcomes including child neurodevelopment. Studies are needed to determine
clinically meaningful definitions of iron deficiency and overload in pregnancy.
Keywords: nutrients; fetal programming; long term outcomes; gestation; offspring
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1. Introduction
Iron is essential in pregnancy for maternal health as well as fetal growth and de-
velopment [1,2]. Because iron deficiency anemia affects billions of people worldwide,
many studies have focused on the impact of low hemoglobin levels on pregnancy out-
come [2,3]. However, iron is not only required for hemoglobin synthesis, but is crucial for
many additional processes including intracellular oxygen transport, cellular respiration,
myelination, neurotransmitter production, and cell proliferation [4]. These processes may
be compromised in iron deficiency, even in the absence of anemia [5]. Presently, iron
status is monitored by biomarkers, such as serum ferritin, transferrin saturation, or soluble
transferrin receptor concentration (sTfR) [6]. Clinical meaningful cut-offs for iron deficiency
or iron overload in pregnancy and preferred methods have not yet been defined [7].
Iron deficiency in pregnancy generates risks for both the mother and her offspring.
However, evidence for improved clinical outcomes upon routine iron supplementation
other than for hematological parameters, is still lacking [2]. At the other end of the spec-
trum, human and animal studies have shown that excess iron is potentially harmful [7].
Iron excess causes oxidative stress, induces cellular damage, and is associated with a variety
of health problems, including cardiovascular risk, pregnancy diabetes, and fetal complica-
tions [8–10]. Whilst the body is capable of limiting absorption of iron, controlled excretion
of excess iron is not possible [10]. Therefore, the World Health Organization Guidelines
recommending routine administration of iron supplements in pregnancy, without first
clinically monitoring iron biomarkers, have been questioned [11]. Concern has been raised,
especially in high income countries, over iatrogenic iron overload [9,12]. Two cohort stud-
ies have confirmed a U-shaped risk curve of maternal hemoglobin, reflecting a higher
risk of adverse pregnancy outcomes among women with highest or lowest hemoglobin
concentrations in pregnancy [13,14]. To what extend this non-linear adverse health effect
is explained by the underlying iron status needs further study, as anemia may also occur
in normal iron status, and high hemoglobin in pregnancy may reflect impaired plasma
volume expansion [15]. However, the findings in early pregnancy, when hemodilution is
still limited, suggest that other mechanisms, such as iron overload, may play a role.
Environmental factors in utero can alter fetal growth and organ development with
a potential impact on the offspring’s longer-term health [16]. Studies on maternal iron
deficiency and neurodevelopmental outcome suggest that iron status in pregnancy is
such a key factor [17]. However, most studies have only examined the effect of iron
supplementation and on short-term outcomes only [18]. A large systematic review on
iron supplementation found an effect on maternal hemoglobin but not on child outcomes
at birth [2]. Another review found a poor correlation between maternal and neonatal
hemoglobin just after birth [19]. An overview of the longer-term consequences of maternal
iron status on child health is still lacking. This is relevant to the discussion on general
administration of iron supply versus personalized iron supplementation in pregnant
women. The aim of this study was to systematically review and analyze the literature on
maternal iron status in pregnancy and health outcomes in the offspring after birth.
2. Methods
2.1. Search Strategy and Study Selection
A systematic review was conducted with adherence to the Preferred Reporting Items
of Systematic Review and Meta-Analysis (PRISMA) guidelines [20] and the pre-specified
protocol was registered at PROSPERO (CRD42020162202). A search strategy was developed
in collaboration with a clinical librarian to search Embase, Medline Ovid, Web of Science,
Cochrane Central, and Google Scholar (Supplementary methods) from inception of the
respective databases until 21 January 2021. After removing duplicates, two reviewers
(H.G.Q.P. and F.C.) independently screened all titles and abstracts for eligibility. Full texts
and reference lists were then screened independently. The final study selection was based
on consensus between both reviewers and, if necessary, disagreement was resolved by
arbitration by a third reviewer (M.J.V.).
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Observational and intervention studies were eligible for inclusion if they investigated
the association between maternal iron status at any stage of pregnancy, in relation to
child health outcomes. Inclusion criteria were as follows: (1) iron status measured during
pregnancy by (ratios of) serum ferritin, transferrin, transferrin saturation, or total iron
binding capacity, iron, sTfR, or genetic proxies for any of these parameters; and (2) any
child outcome being assessed after birth (at any age and into adulthood) related to health,
development, or wellbeing. In the selection procedure, the following exclusion criteria were
applied: (1) intervention studies in which assessment of iron status was done only before
(not during/after) iron supplementation, as iron supplementation does not always lead to
higher iron status depending on physiological and environmental factors; (2) availability of
solely maternal hematological markers (e.g., hemoglobin, hematocrit, and/or erythrocytes),
while more specific markers for iron status in pregnancy are lacking; (3) only fetal or birth
outcomes (such as birth weight, preterm birth) or measurements in umbilical cord blood,
while outcomes after birth are missing; (4) report not written in English; (5) animal studies;
(6) abstracts, reviews, or commentaries not reporting original data; (7) studies whereby no
abstract or full text was available (after internet search, national and international library
requests, and addressing corresponding authors by email).
2.2. Data Extraction and Reporting
Standardized worksheets (Microsoft Excel™, Microsoft Corporation, Redmond, WA,
USA, 2010) were used to systematically manage study selection, methodological quality
assessment, and data extraction. The study characteristics included: year of publication,
country income (low, lower-middle, upper-middle, high) [21], sample size, study design,
use of iron supplementation, risk of bias, stage of pregnancy at iron measurement (first,
second, and third trimester or peri-partum), maternal iron biomarker, cut-off used, outcome
measure, and child age at outcome measurement. Mean ferritin values for the total study
population or of the lower and higher category being used in the comparisons were
recorded. If no mean was reported, we calculated the mean based on the reported median
and measures of variability [22]. The effect of lower or higher iron status in the mother was
categorized into harmful, neutral, or beneficial for the child, based on the reported results.
Data and associations were extracted by one reviewer and then independently verified for
accuracy and completeness by a second reviewer. If necessary, discrepancies were resolved
by consensus with a third reviewer (M.J.V.)
2.3. Quality Assessment and Data Analysis
The methodological quality of each study was independently assessed by two review-
ers H.G.Q.P. and F.C. using the quality score presented in the Newcastle Ottawa Scale [23].
In accordance with the guidelines, customized worksheets were designed for the cohort
studies, intervention trials, and case-controlled studies. Studies were scored one to nine
points and were categorized as low (7–9 points), medium (4–6 points), or high (1–3 points)
risk of bias, based on appraisal of three domains, namely selection, comparability, and
outcome. The following specific definitions were used: representativeness was considered
high if the sample was representative of all pregnant women in the general community. As-
certainment of iron status was considered secure if adequate iron measures were assessed
in blood and considered sufficient if objective indirect measures of iron status were used
such as genetic proxies for iron markers. Stage of pregnancy was considered an important
factor to control for in all studies [24], as was inflammation as ferritin is an acute phase
protein that rises during inflammation [25].
Meta-analysis was considered only if 3 or more studies reported sufficient data on the
association of the same iron marker in pregnancy and the same child health outcome. If an
outcome was measured at multiple points in time, the measurement closest to the age of
6 months was used, as outcomes were most commonly reported at this age. Mean differences
(MD) and associated 95% confidence intervals (CIs) in outcomes were calculated between
children of mothers with iron deficiency (or low iron status) and children of mothers with
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higher iron status (normal or high range). Heterogeneity was evaluated by chi-square Q and
I2 statistics. Given the high variance expected due to study heterogeneity, a random-effects
model was used. The meta-analysis was done using Cochrane Review Manager software
(REVMAN version 5.3, The Nordic Cochrane Centre, Copenhagen, Denmark) and R Software
version 3.5.3. To explore the nature of heterogeneity, meta-regression was performed on the
study characteristics. Multi-collinearity of study characteristics was evaluated in plots as
well as correlation tests. The robustness of models was tested using permutation tests [26].
Publication bias was evaluated by funnel plots and Egger’s tests (cut-off p-value < 0.05).
3. Results
For the initial screening of titles and abstracts, 8139 studies, published between 1975
and January 2021, were identified. Of these, 142 papers were fully read and led to the
identification of 41 studies meeting the inclusion criteria. Scanning reference lists led to the
inclusion of three more studies, resulting in a total of 44 studies [27–70] (Figure 1).
Study characteristics are summarized in Tables 1–4 and Supplementary Table S1. The
reports describe sample sizes ranging from 26 to 94,209 per study, resulting in a total of
127,849 mother–child pairs included in this review. The studies originate from 23 countries
and describe populations in low (9%), middle (43%), and high-income (48%) countries.
Thirty-six papers (80%) describe cohort studies (31 prospective and four retrospective),
five studies are randomized controlled trials with measurement of maternal iron status
(during or after supplementation), and four are case control studies. Of note, in all clinical
trials and in some of the cohort studies, iron supplementation occurred (n = 29; 66%). Iron
supplementation was most commonly prescribed routinely from study inclusion until the
end of pregnancy as 60 mg daily enteral doses, alone or in combination with folic acid
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Figure 1. PRISMA flow diagram.
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Table 1. Studies on maternal iron status and child iron status after birth.


















Rios [27] * 1975 USA H Cohort (S) M 26 General NR T-test SF, Fe, TSAT,TIBC SF < 9 µg/L PP SF, TSAT 6 d
Murray [28] * 1978 Niger L Cohort M 49 Famineconditions NA NR Fe, TSAT
TSAT < 10% vs.
TSAT > 60% PP SF, TSAT 6 m
Kilbride [29] * 2000 Jordan U-M Case control (S) H 195 Refugees 15.2 ‡ T-test SF, Fe, TSAT,(TIBC)
Anemia,
SF < 12 µg/L PP SF
3, 6, 9,
12 m
Poyrazoğlu [30] * 2011 Turkey U-M Cohort (S) M 92 General 33 ‡ ANOVA SF, Fe, TSAT,TIBC Anemia and (S) II, PP SF, TSAT 3, 6, 12 m
Hanieh [31] * 2013 Vietnam L-M Clinical trial (S) L 1168 General 28.4 § MLR SF, (sTfR,sTfR/SF)
(S),
SF < 15 µg/L III SF 6 m
Kulik [32] * 2016 Poland H Cohort (S) M 44 General 22 ‡ corr SF, sTfR SF < 15 µg/L PP SF 3 d
Matias [33] * 2018 Bangladesh L-M Clinical trial (S) L 1117 General NR MLR SF, sTfR SF < 12 µg/L III SF 6 m
Positive
association
Puolakka [34] * 1980 Finland H Cohort (S) H 47 General NR MWU SF (Fe, TF,TSAT, TIBC) SF < 50 µg/L PP SF 6 m
Milman [35] * 1987 Denmark H Cohort (S) M 56 General 21 † MWU SF (Fe, TF,TSAT) SF < 15 µg/L PP SF 5 d
Morton [36] 1988 UK H Cohort (S) M 51 General NR T-test SF SF < 10 µg/L III SF 6 m
Preziosi [37] * 1997 Niger L Clinical trial (S) M 197 General NR T-test SF (Fe, TSAT) SF < 12 µg/L II, PP SF (Fe,TSAT) 3, 6 m
Liu [38] * 2015 China U-M Cohort L 140 General 19.9 ‡ T-test SF, sTfR Anemia III sTfR (SF) 6 m(42 d, 4 m)
Santos [39] * 2018 China U-M Clinical trial (S) L 1194 General NR MLR SF, sTfR II, III SF, sTfR 9 m




13.4 ‡ MLR SF, (sTfR) SF < 12 µg/L III SF, (sTfR) 6 m (12 m)
Shukla [41] * 2019 India L-M Cohort L 163 General 62.6 ‡ T-test, corr SF Anemia PP SF 14 wk
Country income according to World Bank classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 accessed on 20 July 2020 ); corr, correlation; d, Days; I, II, III, gestational trimester;
H, high; L, low; L-M, lower-middle; U-M, upper-middle; MWU, Mann–Whitney U-test; M, medium; m, months; MLR, multiple linear regression; NA, not applicable; PP, peri-partum; SF, serum ferritin represents
reported (or calculated); sTfR, soluble transferrin receptor; (S), maternal iron supplementation, TF, transferrin; TSAT, transferrin saturation; TIBC, total iron binding capacity; wk, week; y, year. * Studies reporting
multiple outcomes; †, median; ‡, mean; §, geometric mean; values in the total study population. Studies are grouped by the direction of the association between maternal iron status and child hemoglobin.
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Table 2. Studies on maternal iron status and child hemoglobin concentrations after birth.


















Rios [27] * 1975 USA H Cohort (S) M 26 General NR T-test SF, Fe, TSAT,TIBC SF < 9 µg/L PP Hemoglobin 6 d
Murray [28] * 1978 Niger L Cohort M 49 Famineconditions NA NR Fe, TSAT
TSAT < 10% vs.
TSAT > 60% PP Hemoglobin 6 m
Puolakka [34] * 1980 Finland H Cohort (S) H 47 General NR MWU SF (Fe, TF,TSAT, TIBC) SF < 50 µg/L PP Hemoglobin 6 m
Milman [35] * 1987 Denmark H Cohort (S) M 56 General 21 † MWU SF (Fe, TF,TSAT) SF < 15 µg/L PP Hemoglobin 5 d
Turkay [42] 1995 Turkey U-M Cohort M 27 General 13.5 ‡ T-test, corr SF, Fe, TSAT SF < 12 µg/L II, III Hemoglobin 3 m
Preziosi [37] * 1997 Niger L Clinical trial (S) M 197 General NR T-test SF (Fe, TSAT) SF < 12 µg/L II, PP Hemoglobin 3, 6 m
Poyrazoğlu [30] * 2011 Turkey U-M Cohort (S) M 92 General 33 ‡ ANOVA SF, Fe, TSAT,TIBC Anemia and (S) II, PP Hemoglobin 3, 6, 12 m
Hanieh [31] * 2013 Vietnam L-M Clinical trial (S) L 1168 General 28.4 § MLR SF (sTfRsTfR/SF)
(S),
SF < 15 µg/L III Hemoglobin 6 m
Liu [38] * 2015 China U-M Cohort L 140 General 19.9 ‡ T-test SF, sTfR Anemia III Hemoglobin 42 d, 4 m,6 m
Kulik [32] * 2016 Poland H Cohort (S) M 44 General 22 ‡ corr SF, sTfR SF <15 µg/L PP Hemoglobin 3 d
Matias [33] * 2018 Bangladesh L-M Clinical trial (S) L 1117 General NR MLR SF, sTfR SF <12 µg/L III Hemoglobin 6 m
Positive
association
Kilbride [29] * 2000 Jordan U-M Case control (S) H 195 Refugees 15.2 ‡ T-test SF, Fe, TSAT(TIBC)
Anemia,
SF <12 µg/L PP Hemoglobin
9, 12 m
(3, 6m)
Santos [39] * 2018 China U-M Clinical trial (S) L 1194 General NR MLR SF, sTfR II, III Hemoglobin 9 m




13.4 ‡ MLR SF, (sTfR) SF <12 µg/L III Hemoglobin 6 m (12 m)
Shukla [41] * 2019 India L-M Cohort L 163 General 62.6 ‡ T-test, corr SF Anemia PP Hemoglobin 14 wk
Country income according to World Bank classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 accessed on 20 July 2020 ); corr, correlation; d, Days; I, II, III, gestational trimester;
H, high; L, low; L-M, lower-middle; U-M, upper-middle; MWU, Mann–Whitney U-test; M, medium; m, months; MLR, multiple linear regression; NA, not applicable; PP, peri-partum; SF, ferritin represents
reported (or calculated); sTfR, soluble transferrin receptor; (S), maternal iron supplementation; TF, transferrin; TSAT, transferrin saturation; TIBC, total iron binding capacity; wk, week; y, year. * Studies reporting
multiple outcomes; †, median; ‡, mean; §, geometric mean; values in the total study population. Studies are grouped by the direction of the association between maternal iron status and child hemoglobin.
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Table 3. Studies on maternal iron status and child neurobehavioral outcomes.















Zhou [43] 2006 Australia H Clinical trial (S) L 430 General 14 ‡ T-test SF (S),SF < 12 µg/L III
Intelligence: reasoning,
memory 4 y
Davidson [44] 2008 Seychelles H Cohort (S) L 229 General NR MLR SF, sTfR II Psychomotor 5, 9, 25,30 m
Rioux [45] 2011 Canada H Cohort (S) M 63 General NR MLR SF SF < 10 µg/L III Cognition 6 m
Lewis [46] 2014 UK H Cohort (S) L 11,696 General NA MLR IV Cognition 8 y
Tran [47] 2014 Vietnam L-M Cohort L 418 General 17.3 ‡ MLR SF SF < 15 µg/L I, III Motor 6 m
Lou [48] 2015 China U-M Cohort L 69 General 17.4 ‡ ANCOVA SF SF < 16 µg/L III Auditory brainstemresponse 3, 10 m





Higher maternal iron status associated with adverse child outcome
Hanieh [31] * 2013 Vietnam L-M Clinical trial (S) L 713 General 28.4 § MLR SF, (sTfR,sTfR/SF)
(S),
SF < 15 µg/L III
Cognition, language,
motor 6 m
Higher maternal iron status associated with better child outcome
Vaughn [50] 1986 USA H Cohort (S) H 115 General NR T-test TIBC(SF, Fe) Irritability III
(Neonatal behavior),
Irritability 3d (5 m)
Hernández [51] 2011 Spain H Cohort (S) L 216 General NR MLR SF, TSAT SF < 12 µg/L I, II,III Neonatal behavior
Neonatal
period
Tran [52] 2013 Vietnam L-M Cohort L 378 General NR MLR SF SF < 15 µg/L I, III Cognition 6 m




42.7 ‡ corr SF SF < 20 µg/L I Memory 5 y




6.2 § MLR SF, sTfR/SF(sTfR) III
Cognition, language,
motor 12 m
Berglund [55] 2017 Spain H Cohort (S) L 331 General 16.7 ‡ ANCOVA SF, TSAT SF < 15 µg/L III,PP
Cognition, language,
motor 18 m
Santos [39] * 2018 China U-M Clinical trial (S) L 1194 General NR MLR SF, sTfR II, III Motor 9 m
Choudhury [56] 2015 India L-M Cohort L 90 General 36.9 ‡ MLR SF PP Auditory brainstemresponse 24 to 48 h
ElAlfy [57] 2018 Egypt L-M Case control L 100 General 55.6 ‡ T-test SF (Fe, TSAT,TIBC) SF < 15 µg/L PP
Auditory brainstem
response 48 h, 3 m
Arija [58] 2019 Spain H Cohort (S) L 2032 General NR MLR SF SF < 12 µg/L I
Memory, attention,
flexibility and inhibition 7 y
Kupsco [59] 2020 Mexico U-M Cohort (S) L 571 General 36.7 ‡ GAM SF SF < 15 µg/L II, III,PP Memory, motor, cognition 4–6 y
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Table 3. Cont.



















Country income according to World Bank classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 accessed on 20 July 2020 ); corr, correlation; d, Days; I, II, III, gestational trimester;
GAM, generalized additive models; H, high; IV, instrumental variable; L, low; L-M, lower-middle; U-M, upper-middle; MWU, Mann–Whitney U-test; M, medium; m, months; MLR, multiple linear regression;
NA, not applicable; PP, peri-partum; PRM, Poisson regression model; SF, ferritin represents reported (or calculated); sTfR, soluble transferrin receptor; (S), maternal iron supplementation, TF, transferrin; TSAT,
transferrin saturation; TIBC, total iron binding capacity; wk, week; y, year. * Studies reporting multiple outcomes; ‡, mean; §, geometric mean; values in the total study population. Studies are grouped by the
direction of the association between maternal iron status and child neurobehavioral outcomes.
Table 4. Studies on maternal iron status and other child outcomes after birth.

















Cardiovascular and bone outcomes
Ganpule [61] 2006 India L-M Cohort (S) L 797 General NR MLR SF SF < 12 µg/L II Bone mass 6 y
Alwan [62] 2012 UK H Cohort L 348 General NA MLR IV Blood pressure,adiposity
40–41 y
Alwan [63] 2015 UK H Cohort (S) L 362 General 37.5 ‡ MLR SF, sTfR,sTfR/sF SF < 15 µg/L I Arterial Stiffness 6 wk
Pulmonary outcomes
Nwaru [64] * 2014 UK H Cohort (S) L 157 General 28.4 ‡ MLR SF, sTfR,sTfR/sF SF < 15 µg/L I, PP Wheeze, allergy 1, 2, 5, 10 y
Nwaru [64] * 2014 UK H Cohort (S) L 157 General 28.4 ‡ MLR SF, sTfR,sTfR/sF SF < 15 µg/L I, PP Lung function 1, 2, 5, 10 y
Bédard [65] 2018 UK H Cohort (S) L 6002 General NA MLR IV Lung function 7.5 y
Miscellaneous outcomes
Abioye [66] 2016 Tanzania L Cohort (S) L 600 General 47.5 † MLogR SF, sTfR SF ≤ 12 µg/L I, II,PP Infant mortality 6 w
Hanieh [67] 2015 Vietnam L-M Nested-cohort(S) L 1046 General 28 † MLR SF I, III Infant growth 6 w, 6 m
Goldenberg [68] 1998 USA H Nested-cohort L 223 Women withPRM 38.3 ‡ MLogR SF II, PP Neonatal sepsis
Neonatal
period
Størdal [69] 2018 Norway H Case control (S) L 94,209 General NA CPHR IV Diabetes type 1 8 to 17 y
Dai [70] 2015 Turkey U-M Case control M 254 General 24.3 ‡ T-test SF, Fe Stage of ROP III Retinopathy ofprematurity Infancy
Country income according to World Bank classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 accessed on 20 July 2020 ); corr, correlation; CPHR, Cox proportional hazard
regression; d, days; I, II, III, gestational trimester; H, high; IV, instrumental variable; L, low; L-M, lower-middle; U-M, upper-middle; MWU, Mann–Whitney U-test; M, medium; m, months; MLR, multiple linear
regression; MLogR, multiple logistic regression; NA, not applicable; PP, peri-partum; PRM, premature rupture of the membranes; ROP, retinopathy of prematurity; SF, ferritin represents reported (or calculated);
sTfR, soluble transferrin receptor; (S), maternal iron supplementation; TF, transferrin; TSAT, transferrin saturation; TIBC, total iron binding capacity; wk, week; y, year. * Studies reporting multiple outcomes;
†, median; ‡, mean; values in the total study population.
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3.1. Maternal Iron Status
Serum ferritin was used in 39 studies (89%) to classify maternal iron status (Tables 1–4).
Other biomarkers included serum iron, sTfR, or the sTfR:ferritin ratio. The lowest and the
highest mean maternal serum ferritin were found in cohorts from Philippines (13.4 µg/L) [40]
and India (62.6 µg/L) [41]. In many studies, mean ferritin concentrations were not specified
(Tables 1–4). Twenty-seven studies (61%) categorized women in order to compare iron defi-
ciency or “low” to normal or “higher” iron status, whilst others categorized according to
supplementation or health status. As no definitions are universally agreed upon, we found
different cut-offs being applied to ferritin ranging from ferritin < 9 µg/L in an American
study [27] to <50 µg/L in a Finnish study [34]. Mostly, the lower category was based on
a ferritin <12 (n = 10 studies). Studies not comparing categories analyzed biomarkers as
continuous variables in linear models. The majority of studies (91%) focused on low(er) ma-
ternal iron status or iron deficiency, whilst iron status above normal or iron excess was the
focus in four studies only [31,67–69]. Four recent studies used maternal common genetic
variants as proxies for iron stats [46,62,65,69]. These included twelve single nucleotide
polymorphisms (SNPs) at different locations associated with lower iron status and two in
the hemochromatosis (HFE) gene associated with iron overload. This gene is involved in
intestinal absorption and cellular iron uptake and may impact trans-placental transport of
iron. [71].
Maternal measurements were timed throughout pregnancy, with most of them occur-
ring during the third trimester or at birth. Of the 10 studies that examined the first trimester
of pregnancy, reflecting the period of organogenesis, only four explored outcomes beyond
infancy [53,58,60,64]. One found impaired memory in 5-year-old children of mothers with
anorexia nervosa and low ferritin levels [53]. Another showed associations between mater-
nal lower iron status, child wheezing, and impaired lung function [64]. The third found
that lower maternal ferritin levels were associated with lower child scores in memory and
executive functioning at 7 years of age [58]. The last one found an association of lower
maternal ferritin and symptoms of poor attention in 4- to 5-year-old boys, though not in
girls [60].
3.2. Quality Assessment
Risk of bias scores ranged from 3 to 9 (median 8), with most studies having a low
(n = 32; 71%) or medium (n = 10; 22%) risk of bias (Table 1). Study samples appeared
reasonably representative of pregnant women in the general population, however, nine
studies had no description of the derivation of the cohort. Blind assessment of the outcome
was described in 12 cohort studies. The most common risk of bias was the lack of control
for inflammation whilst studying ferritin, an issue that was properly addressed in only
14 studies. These studies either adjusted the cut-off of ferritin in case of inflammation
(n = 2) [40,49], excluded women with high inflammation markers (n = 4) [38,41,57,58],
excluded cases with high ferritin (n = 1) [51], statistically corrected for inflammation
(n = 1) [33], used genetic instrumental variables (n = 4) [46,62,65,69], or used a combination
of these methods (n = 2) [47,55]. From eight studies, data on sTfR were available, which is
a marker that inversely correlates with the amount of iron available for erythropoiesis and
is less affected by inflammation [3].
3.3. Child Outcome
Details on study designs (year of publication, country, country income, and risk
of bias), maternal iron status (biomarker used, ferritin cut-offs, or mean ferritin levels,
and pregnancy stage), child outcomes (description and age), and associations observed
(direction of effect) are summarized in Tables 1–4. These also show whether the association
of a higher maternal iron status, as compared to iron deficiency or relative to lower iron
state in linear models, correlates with a beneficial, detrimental, or indifferent outcome in
the child.
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The reported child health outcomes varied widely. Outcome was predominantly
measured in early infancy (n = 32; 73%), but ages ranged from 24 h after birth until
school-age. Only one study focused on adult outcomes, reporting no association between
maternal iron status and off-spring blood pressure and adiposity at 40 years of age [62].
Sixteen studies examined the iron status or hemoglobin concentrations (or both) of children,
though not after 12 months of age (Tables 1–4). Twenty-one studies reported more clinical
or functional outcomes, including different aspects of neurodevelopment (n = 18) and
hearing status (n = 3) [56–58] (Table 3). The remaining ten studies examined cardiovascular
risk factors (n = 2) [62,63], pulmonary issues (n = 2) [64,65], and all others examined bone
mass, retinopathy of prematurity, infant mortality, neonatal sepsis, infant growth, and Type
1 diabetes, respectively (Table 4).
The 16 studies on child iron status or anemia were mostly 83% carried out in high and
middle-income countries. Sample sizes of these studies ranged from 26 to 1194 mother-
child pairs. The majority had a moderate or low risk of bias. Fourteen studies provided
sufficient data for meta-analysis on the outcomes of four iron-related hematological pa-
rameters. No significant association of maternal iron status (i.e., serum ferritin) and child
hemoglobin, ferritin, or transferrin saturation was found (Table 2, Figure 2A–C). The only
consistent association between maternal ferritin and child iron status was found in sTfR
(Figure 2D). Heterogeneity was generally high, with I2 ranging from 54% for the studies on
child transferrin saturation to over 95% for the other outcomes. Meta-regression suggests
that associations with child hemoglobin are stronger in more recent studies, whereby
mothers were tested later in pregnancy and the child outcomes were assessed at a younger
age (combined explained variance 96%, p < 0.01). Heterogeneity in the child ferritin
studies was mainly explained by stronger associations found in higher income countries
(explained variance 77%, p = 0.02). Study design, iron supplementation, and quality did
not significantly explain variance in effect estimates (Supplementary Table S2). Sensitivity
analyses in subgroups to assess the robustness of our findings did not materially change
our conclusions. Publication bias was considered unlikely (Supplementary Figure S1).
Neurodevelopmental outcomes were the focus of 20 studies (45%) with sample sizes
ranging from 63 to 11,696 (Table 3). All of these studies were conducted in high- and
middle-income countries, except for one study from Benin [49]. Only one of the studies
on neurodevelopment, published in 1986, showed a high risk of bias [50]. Except for one
Mendelian randomization study [46], all neurodevelopmental studies measured serum
ferritin in pregnancy. The neurodevelopmental outcomes examined included cognition,
motor development, and child behavior, evaluated in infancy and/or childhood up to
8 years of age [46]. The majority of studies used standardized neurodevelopmental tests,
including cognitive, motor, verbal, memory functioning, and neonatal behavior. Results
varied, with only 12 out of the 20 studies reporting better neurodevelopmental outcome
in children from mothers with higher iron status as compared to mothers whose iron
status was considered low. Two of the three studies on auditory brainstem response,
measured between 24 h and 3 months of age, found a positive association of maternal
ferritin concentrations in pregnancy and child’s hearing later in later life [56,57]. Studies
on the various other outcomes are summarized in Table 4.
We identified four reports on three studies reporting on high maternal iron sta-
tus, as opposed to normal, and its possible relationship with adverse outcomes in
children [31,67–69]. In a Vietnamese cluster randomized trial, ferritin was higher in women
with daily dosage, as compared to those with intermittent dosage of iron supplementa-
tion [31,67]. Follow-up at 6 months of age showed lower cognitive scores and lower length
for age in children of mothers with higher ferritin levels in pregnancy [31,67]. The effect on
infant growth was largely mediated through birth weight, which was lower in mothers
with higher ferritin [67]. The authors explain their findings by deleterious fetal effects of
iron supplementation in women who already have normal iron stores. Harmful effects
of iron supplementation in women without iron deficiency was also suggested in a very
large Norwegian cohort [69]. They found an increased risk of childhood diabetes Type
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I in children of mothers with iron supplementation or with common genetic variants in
the HFE gene that are linked to high/intermediate iron stores. Their findings likely reflect
intra-uterine effects, as the association was not explained by the HLE genotype of the
child [69]. The fourth study on high maternal iron status reported an association between
elevated ferritin levels and neonatal sepsis among women with premature rupture of mem-
branes, likely to be explained by an acute phase response during infection [68]. Studies
specifically exploring a U-shaped curve for risk were not found. None of the included
studies applied non-linear models to identify risks of both iron deficiency and iron excess
on the same outcome. The only study comparing three maternal ferritin categories was in
African women under famine conditions back in 1978, who were without supplementation.
No U-shaped curve for child hematological measures was found [28].
Figure 2. Forest plot of the associations of maternal serum ferritin levels during pregnancy with child hemoglobin concen-
trations (A), child serum ferritin concentrations (B), child transferrin saturation (C), and child soluble transferrin receptor
concentrations (D). Random-effect meta-analysis showing the pooled mean difference child hemoglobin concentrations
comparing high and low maternal serum ferritin in pregnancy. CI, confidence interval; IV, inverse variation; SF, serum
ferritin; DF, degrees of freedom.
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4. Discussion
In this systematic review on maternal iron status in pregnancy, we summarize 44 stud-
ies on a wide range of child health outcomes measured shortly after birth into adulthood.
The main finding of the review is that a normal or higher maternal iron status in pregnancy,
as compared to iron deficiency or lower iron status, was either associated with child health
benefits (46% of studies) or showed no significant association at all (48%). Meta-analyses of
studies on biochemical outcomes found a significant negative association between maternal
iron status and child sTfR levels but no association with child ferritin, transferrin saturation,
and hemoglobin. As sTfR is a reliable biomarker of low iron status which is less affected
by inflammation, our findings suggest that maternal and child iron status are indeed
related, which is in line with earlier reviews on short-term effects including cord blood
studies [72–75]. After infancy, studies mainly focused on neurodevelopmental outcomes,
with 12 out of 20 studies reporting better outcomes in children of mothers with higher
iron status and one reporting harmful effects of higher iron status [31]. These outcomes
included cognition, motor function, language, and memory. Additionally, child hearing
may benefit from a higher maternal iron status. The magnitude of the global effects of iron
deficiency remains underexposed, with only one of the neurodevelopmental studies being
carried out in a low-income country.
The finding that in nearly half of the studies, maternal iron status is not associated
with child health outcome, may have different explanations.
(1) It is possible that maternal iron status is not associated with these outcomes because
the studied outcomes vary in their sensitivity to this exposure. It could be that
compensating regulatory mechanisms may in fact protect the child from disturbance
of the maternal iron balance. For example, the placenta can actively transport iron
from the mother to the fetus, thereby protecting the latter from iron deficiency, even
at the expense of maternal iron stores [24].
(2) The resulting effects may be too modest to be detected at a later age, especially in
small studies. Indeed, our meta-regression on hemoglobin studies suggests weaker
associations when maternal and child hemoglobin measurements are further apart. If
effects are modest at a later age, the clinical impact is likely to be considered low.
(3) Existing effects may have been missed due to the high heterogeneity regarding study
populations, laboratory methods, and cut-offs applied. Definitions of iron deficiency
varied across studies and within countries. This is inevitable as worldwide applicable
definitions of iron deficiency or iron overload in pregnancy have yet to be defined.
(4) Timing of measurements during pregnancy is important as iron stores change dra-
matically during the course of pregnancy. Trimester-specific cut-offs that consider the
physiological increases in blood volume, hemodilution, and iron requirements of the
placenta and fetus are needed. Results may have differed if measurements were more
consistent across studies [76].
(5) During pregnancy, iron supplementation, as well as individual differences in body
weight, dietary intake, micronutrient deficiencies, and iron absorption, may mask
effects of iron deficiency or otherwise in both mother and child [77]. Additionally, iron
intake during earlier infancy including breastfeeding practices and iron enrichment
or supplementation might also influence our results and might explain differences
between countries [15]. These potential confounders or mediators were generally not
analyzed, except for eleven studies that took breastfeeding into account.
(6) Another very likely explanation is that results are biased by inflammation, which is
largely not reported [78]. This is of specific relevance in regions with high prevalence
of (chronic) infections, like tuberculosis, malaria, and other parasitic infections [6].
During states of inflammation, the acute phase protein ferritin rises markedly, even
in the case of iron deficiency. That may explain why no effect was detected on child
iron biomarkers except for sTfR, which is controlled by iron availability and not by
inflammation [3].
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(7) Another possibility is that maternal iron effects are non-linear, as hypothesized earlier
based on the U-shaped risk curve of maternal hemoglobin [13]. If iron deficiency and
iron overload are both harmful, effects may be missed in linear statistical models or
in studies comparing two categories that include both these extremes. We conclude
that there is little evidence to support or reject a U-shaped risk curve of maternal iron
status on specific outcomes.
With only four reports being found on high or excessive maternal iron and all of them
reporting adverse outcomes in the offspring [31,67–69], we propose that more research on
long-term effects of iron overload is urgently needed, especially in populations with low
prevalence of iron deficiency. The possible harmful effects of high maternal iron status on
the fetus supports region-specific individualization of iron supplementation to prevent
iatrogenic iron overload. The findings call for a global approach in establishing clinically
meaningful definitions of iron deficiency and overload that are pregnancy-stage–specific,
and are based on short- and long-term outcomes.
Strengths and Limitations
To our knowledge, this study is unique in providing a comprehensive systematic
review and meta-analysis of maternal iron status during pregnancy and child health
outcomes after birth. Strengths of our analysis are the broad search strategy in accordance
with current guidelines, including both observational and interventional studies. Although,
this study has some limitations. By excluding studies not written in English, a language bias
may have been introduced. By applying no restriction on publication date or on laboratory
techniques used, we may also have selected lower-quality studies that diluted the effects.
We decided to exclude studies on maternal hemoglobin that did not report on specific
iron biomarkers. Hemoglobin is often used as a proxy for iron status, but it is neither a
sensitive nor a specific measure of iron deficiency [79]. That is because hemoglobin is not
solely determined by iron status, but also by residential altitude [80], ethnicity, nutritional
status, hemoglobinopathies, as well as infectious and chronic diseases [81]. Because iron
has many other biochemical functions in all cell types, we expected that child health effects
of the maternal iron status are of critical importance beyond the effects on hemoglobin.
We cannot rule out that by focusing on maternal iron status and not on maternal anemia,
we may have missed important studies that used hemoglobin as a proxy for iron status.
However, a very recent review on maternal hemoglobin in pregnancy did not find data on
long-term child health outcomes [82].
Furthermore, factors explaining the differences in maternal iron status did not fall
within the scope of this review. In two-thirds of studies, iron supplementation was involved,
but other unmeasured factors, including socioeconomic status, health status, diet, and
genetic factors may also have played a role. The risk of confounding needs to be considered
when interpreting the results of the predominantly observational studies. Additional
limitations include high heterogeneity amongst the studies and the absence of assessment
of the likely causal pathways, limiting the ability to form solid conclusions. Based on the
current literature, it is not feasible to define the physiologic range or to determine useful
clinical cut-offs for adverse iron status in pregnancy.
5. Conclusions
We found that maternal iron status in pregnancy is likely to be associated with child
iron status after birth, but only to a modest extent, with not all iron biomarkers following
this trend. Findings from a very heterogeneous set of studies may suggest beneficial
effects of higher maternal iron status on other outcomes including child neurodevelopment.
Long-term effects of maternal iron status above normal need further exploration. Our
analysis highlights the need for more high-quality studies that look beyond hemoglobin
concentrations and beyond birth, thereby determining the physiological range and defining
outcome-based definitions of iron deficiency and iron overload in pregnancy.
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